Cybin Inc. (CYBN.NE) Research

Cybin Inc. is a biopharmaceutical firm dedicated to advancing treatments derived from psychedelic compounds. Its active research and development portfolio features several key candidates: CYB003, a modified psilocybin compound targeting major depressive and alcohol use disorders; CYB004, a deuterated form of dimethyltryptamine aimed at anxiety conditions; and CYB005, a phenethylamine derivative designed to address neuroinflammation. Additionally, Cybin has introduced EMBARK, a therapeutic approach incorporating psychedelic-assisted psychotherapy. The company's main operations are situated in Toronto, Canada.

Market snapshot

Symbol
CYBN.NE
Price
$6.50
Day change
-1.07%
Market cap
$111.1M
P/E ratio
-1.57x
52-week range
5.3-15.27
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 10 days

Peer companies

  • CareRx Corporation (CRRX.TO)
  • Medical Facilities Corporation (DR.TO)
  • Eupraxia Pharmaceuticals Inc. (EPRX.TO)
  • Fennec Pharmaceuticals Inc. (FRX.TO)
  • Helix BioPharma Corp. (HBP.TO)
  • Jushi Holdings Inc. (JUSH.CN)
  • Satellos Bioscience Inc. (MSCL.TO)
  • NervGen Pharma Corp. (NGEN.V)

Open Cybin Inc. (CYBN.NE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.